Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.

Galon, Jérôme; Mlecnik, Bernhard; Bindea, Gabriela; Angell, Helen K; Berger, Anne; Lagorce, Christine; Lugli, Alessandro; Zlobec, Inti; Hartmann, Arndt; Bifulco, Carlo; Nagtegaal, Iris D; Palmqvist, Richard; Masucci, Giuseppe V; Botti, Gerardo; Tatangelo, Fabiana; Delrio, Paolo; Maio, Michele; Laghi, Luigi; Grizzi, Fabio; Asslaber, Martin; ... (2014). Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. Journal of pathology, 232(2), pp. 199-209. Wiley 10.1002/path.4287

Preview

Text path4287.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (681kB) | Preview

The American Joint Committee on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) TNM staging system provides the most reliable guidelines for the routine prognostication and treatment of colorectal carcinoma. This traditional tumour staging summarizes data on tumour burden (T), the presence of cancer cells in draining and regional lymph nodes (N) and evidence for distant metastases (M). However, it is now recognized that the clinical outcome can vary significantly among patients within the same stage. The current classification provides limited prognostic information and does not predict response to therapy. Multiple ways to classify cancer and to distinguish different subtypes of colorectal cancer have been proposed, including morphology, cell origin, molecular pathways, mutation status and gene expression-based stratification. These parameters rely on tumour-cell characteristics. Extensive literature has investigated the host immune response against cancer and demonstrated the prognostic impact of the in situ immune cell infiltrate in tumours. A methodology named 'Immunoscore' has been defined to quantify the in situ immune infiltrate. In colorectal cancer, the Immunoscore may add to the significance of the current AJCC/UICC TNM classification, since it has been demonstrated to be a prognostic factor superior to the AJCC/UICC TNM classification. An international consortium has been initiated to validate and promote the Immunoscore in routine clinical settings. The results of this international consortium may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune).

Interest & Impact

Downloads

578 since deposited on 13 Feb 2015
50 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item